CERBA-HEALTHCARE
Cerba HealthCare, a leading global player in medical diagnosis, has been exploring new alternatives to transport biological samples that combine low carbon footprint, shorter time-to-results for patients and prescribers while allowing every patient to benefit from the analytical quality of large capacity laboratory platforms in a timely manner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230307005636/en/
©Delivrone 2023
Over the past couple of weeks, France and Italy, two major affiliates of the Group, hosted drone-enabled sample transport and successfully performed their experimental flights in different conditions.
Jérôme Sallette, Chief Scientific Officer at Cerba HealthCare, comments: “Following the use cases we described in our white paper, the drone flight we experimented in Normandy with Cerballiance is a first step toward a broader and more sustainable approach of our logistic mix for sample transportation. It illustrates the long-standing drive for innovation within the Group and by 2024, we plan to identify how drones will prove an efficient complementary way of carrying biological samples”.
“Last week Cerba HealthCare Italia performed the first drone flight with biological samples embedded, involving some of the medical centers around the Metropolitan City of Milan, specifically in the two sites located in the cities of Opera and Rozzano” adds Stefano Massaro, Chief Executive Officer of Cerba HealthCare Italia. “We are dealing with the first air transport of blood samples not yet tested, experimented by the use of a drone. The result of this adventure today makes us confident and eager to pursue the path of innovation as a landmark of a leading quality service for patients”.
- To access the French flight video: https://youtu.be/rjy0e1kMluM
- To access the Italian flight video: https://www.youtube.com/watch?v=-wOCDJipasc
- To access the white paper: https://www.cerbahealthcare.com/en/drones-medical-logistics-opportunities-and-challenges
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnostics, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on five continents, the Group's 15,000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005636/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of SENQCIA to Noritsu Koki15.1.2026 14:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XI, L.P. has entered into a definitive agreement to sell SENQCIA Corporation (“SENQCIA”), a leading provider of mission-critical building products and solutions in Japan, to Noritsu Koki Co., Ltd., in a transaction that represents a total enterprise value of approximately $519 million. Headquartered in Tokyo, SENQCIA develops, designs and distributes essential structural solutions that enhance the resilience, integrity and long-term safety of buildings and infrastructure. The company’s diversified product portfolio serves a broad range of end-markets and property types that are used in many iconic landmark properties across Japan. SENQCIA’s solutions help address key structural challenges facing Japan, including increasing natural disaster risk and aging infrastructure and building stock. During Lone Star’s ownership, SENQCIA has enhanced its go-to-market strategy and reinforced its operational resilience
Altris and Draslovka Partner to Scale Europe’s First Sodium-Ion Battery Technology Supply Chain15.1.2026 14:00:00 CET | Press release
Altris, a Swedish sodium-ion battery developer, and Draslovka, a global leader in specialty chemicals, have entered a strategic partnership to build Europe’s first industrial-scale sodium-ion cathode value chain. Under the comprehensive agreement that includes a total 19.3 MEUR in-kind investment by Draslovka in Altris, the two companies will scale fully connected production of Altris’ patented sodium-ion cathode active material (CAM) at Draslovka’s facility in Kolín, Czech Republic, supplying up to 350 tonnes of CAM annually. Draslovka and Altris are partnering to convert an existing line at Draslovka’s Kolín facility for production of Altris’ sodium-ion CAM, enabling rapid time-to-market and capital-efficient scale-up. Once ramped, the line will support production of up to 350 tonnes annually – a European-controlled supply equivalent to around 175 MWh of sodium-ion cell capacity. As part of the agreement, Draslovka is making a new in‑kind 19.3 MEUR strategic investment in Altris to c
CPP Investments Increases Commitment to Canadian Market through Northleaf Capital Partners15.1.2026 14:00:00 CET | Press release
Canada Pension Plan Investment Board (CPP Investments) and Northleaf Capital Partners (Northleaf) today announced a significant expansion of their longstanding Canadian investment partnership, supporting the growth and scaling of domestic private companies. CPP Investments has committed to invest an additional C$750 million through its established Canadian mid-market program managed by Northleaf, bringing CPP Investments’ cumulative commitments to the manager to more than C$3 billion since inception. The customized mandate focuses on maximizing net returns through a diversified strategy that includes primary fund commitments to small and mid-market Canadian buyout funds, secondary investments, and direct co-investments focused on the domestic market. “There are compelling investment opportunities in the Canadian market, and our two-decade long partnership with Northleaf has proven to be an effective and scalable way to invest in homegrown businesses with patient, long-term capital,” sa
Vantage Data Centers Completes £200M Tap of Existing £600M Industry-First EMEA Data Center Asset-Backed Securitization (ABS) and Adds New £54M Class B Tranche15.1.2026 14:00:00 CET | Press release
Financing will support the company’s expansion across EMEA to keep pace with AI and cloud demand Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised an additional £254 million in securitized term notes. £200 million was raised through a tap of the existing Class A-2 Notes while £54 million was raised from the new Class B Tranche. This builds on Vantage’s debut public issuance in 2024 raising £600 million, which was the first-ever EMEA data center ABS completed in sterling. The Class A-2 Notes are rated A-, A (low) and A by Standard & Poor’s, Morningstar DBRS and Scope Ratings, respectively. The Class B Notes are rated BBB- by Standard & Poor’s and BBB by Morningstar DBRS and Scope Ratings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115777091/en/ Vantage’s 148MW Cardiff, Wales, campus is one of Europe’s largest hyperscale data center campuses. The new notes
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 13:57:00 CET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom